華潤電力(00836.HK)2月附屬電廠售電量達1384萬兆瓦時 同比增加21.6%
格隆匯3月15日丨華潤電力(00836.HK)發佈公吿,2022年2月附屬電廠售電量達到13,838,649兆瓦時,同比增加了21.6%,其中,附屬風電場售電量達到2,460,720兆瓦時,同比下降了4.9%;附屬光伏電站售電量達到104,686兆瓦時,同比增加了52.6%。
2022年首兩個月附屬電廠累計售電量達到30,668,234兆瓦時,同比增加了10.3%,其中,附屬風電場累計售電量達到4,803,447兆瓦時,同比下降了5.7%;附屬光伏電站累計售電量達到205,558兆瓦時,同比增加了58.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.